GERM
Amplify Treatments, Testing and Advancements ETF
GERM
GERM
Delisted
GERM was delisted on the 5th of September, 2024.
19 hedge funds and large institutions have $2.57M invested in Amplify Treatments, Testing and Advancements ETF in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 7 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
19
Holders Change
-5
Holders Change %
-20.83%
% of All Funds
0.3%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
7
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
1 |
IAIM
International Assets Investment Management
Orlando,
Florida
|
+$240K |
2 |
LPL Financial
San Diego,
California
|
+$34K |
3 |
BHWM
Beaird Harris Wealth Management
Dallas,
Texas
|
+$20 |
Top Sellers
1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.1M |
2 |
Citadel Advisors
Miami,
Florida
|
-$865K |
3 |
Goldman Sachs
New York
|
-$701K |
4 |
Jane Street
New York
|
-$265K |
5 |
UBS Group
Zurich,
Switzerland
|
-$41.6K |